Brukinsa (zanubrutinib)

Brukinsa (zanubrutinib) is a Bruton tyrosine kinase (BTK) inhibitor used to treat adult patients with lymphomas such as mantle cell lymphoma, Waldenström’s macroglobulinemia, and relapsed or refractory marginal zone lymphoma. It was approved by the FDA in November 2019 and by the EMA in November 2020.